1. Bearman SI, Appelbaum FR, Buckner CD, et al.: Regimen-related toxicity and early post-transplant survival in patients undergoing marrow transplantation. J Clin Oncol 6:1562-68, 1988.

2. McSweeney PA, Abhyankar S, Becker C, et al.: Low incidence of early transplant mortality using tacrolimus and mycophenolate mofetil for GVHD prevention after conventional allografting. Blood 100(suppl 1):1623, 2002.

3. McSweeney P, Abhyankar S, Petersen F, et al.: Tacrolimus and mycophenolate mofetil for GVHD prevention after unrelated donor transplants. Blood 102(suppl):2654, 2003.

4. Cutler C, Kim HT, Hochberg E, et al.: Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 10:328-336, 2004.

5. Nash RA, Johnston L, Parker PM, et al.: A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of graft versus host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation: dose escalation of MMF. Blood 102(suppl 1):844, 2003.

6. Gottdeiner JS, Appelbaum FR, Ferrans VJ, et al.: Cardiotoxicity associated with high-dose cyclophos-phamide therapy. Arch Int Med 141:758-763, 1981.

7. Angelucci E, Mariotti E, Lucarelli G, et al.: Sudden cardiac tamponade after chemotherapy for marrow transplantation in thalassaemia. Lancet 339:287-289, 1992.

8. Steinherz LJ, Steinherz PG, Mangiacasale D, et al.: Cardiac changes with cyclophosphamide. Med Ped Oncol 9:417-422, 1981.

9. Larsen RL, Barber G, Heise CT, et al.: Exercise assessment of cardiac function in children and young adults before and after bone marrow transplantation. Pediatrics 89:722-729, 1992.

level and survival time posttransplant. Lower gelsolin levels were associated with a higher chance of dying. The authors postulate that the conditioning regimen produces tissue injury that depletes circulating gelsolin.143

0 0

Post a comment